Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Inclusion Criteria

• •Histologically confirmed diagnosis of melanoma
• •Progressive disease that is not surgically resectable, or metastatic Stage IV
• •Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal
• •No prior chemotherapy
• •Measurable disease
• •ECOG performance status ≤ 1
• •At least 4 weeks and recovery from effects of major prior surgery or other therapy, including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy
• •Prior immunotherapy allowed
• •Adequate organ function